RJFSA
CPRX

Raymond James Financial Services Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.1M Buy
256,688
+2
+0% +$37 0.01% 1209
2024
Q2 		$3.98M Sell
256,686
-1,135
-0.4% -$17.7K 0.01% 1282
2024
Q1 		$4.11M Sell
257,821
-3,611
-1% -$54.4K 0.01% 1245
2023
Q4 		$4.39M Buy
261,432
+23,171
+10% +$317K 0.01% 1155
2023
Q3 		$2.79M Sell
238,261
-8,198
-3% -$110K 0.01% 1315
2023
Q2 		$3.31M Sell
246,459
-231,846
-48% -$3.34M 0.01% 1241
2023
Q1 		$7.93M Buy
478,305
+163,577
+52% +$2.7M 0.02% 786
2022
Q4 		$5.85M Buy
314,728
+14,715
+5% +$227K 0.01% 890
2022
Q3 		$3.85M Buy
300,013
+63,674
+27% +$755K 0.01% 1052
2022
Q2 		$1.66M Sell
236,339
-1,062
-0.4% -$7.79K ﹤0.01% 1546
2022
Q1 		$1.97M Sell
237,401
-180
-0.1% -$1.27K ﹤0.01% 1499
2021
Q4 		$1.61M Sell
237,581
-1,368
-0.6% -$9K ﹤0.01% 1682
2021
Q3 		$1.27M Hold
238,949
– – ﹤0.01% 1797
2021
Q2 		$1.37M Buy
238,949
+1,998
+0.8% +$10.3K ﹤0.01% 1728
2021
Q1 		$1.09M Buy
236,951
+40
+0% +$159 ﹤0.01% 1793
2020
Q4 		$791K Sell
236,911
-25
-0% -$84 ﹤0.01% 1856
2020
Q3 		$704K Sell
236,936
-7,388
-3% -$28.9K ﹤0.01% 1764
2020
Q2 		$1.13M Buy
244,324
+7,423
+3% +$33.4K ﹤0.01% 1418
2020
Q1 		$912K Hold
236,901
– – ﹤0.01% 1250
2019
Q4 		$888K Hold
236,901
– – ﹤0.01% 1605
2019
Q3 		$1.26M Sell
236,901
-635
-0.3% -$3.38K ﹤0.01% 1344
2019
Q2 		$912K Buy
237,536
+635
+0.3% +$2.74K ﹤0.01% 1555
2019
Q1 		$1.21M Hold
236,901
– – 0.01% 1350
2018
Q4 		$455K Hold
236,901
– – ﹤0.01% 1731
2018
Q3 		$895K Hold
236,901
– – ﹤0.01% 1531
2018
Q2 		$739K Hold
236,901
– – ﹤0.01% 1615
2018
Q1 		$566K Buy
+236,901
New +$787K ﹤0.01% 1643
2017
Q4 		– Sell
-15,500
Closed -$39K – 2555
2017
Q3 		$39K Hold
15,500
– – ﹤0.01% 2470
2017
Q2 		$43K Hold
15,500
– – ﹤0.01% 2422
2017
Q1 		$30K Hold
15,500
– – ﹤0.01% 2338
2016
Q4 		$16K Hold
15,500
– – ﹤0.01% 2305
2016
Q3 		$17K Hold
15,500
– – ﹤0.01% 2265
2016
Q2 		$11K Buy
15,500
+1,500
+11% +$1.21K ﹤0.01% 2259
2016
Q1 		$16K Buy
+14,000
New +$21.7K ﹤0.01% 2021

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Raymond James Financial Services Advisors's CPRX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 0% in Q3 2024, buying an estimated $37 and bringing the position to 256,688 shares worth $5.1M. The position accounts for 0.01% of the portfolio, ranked #1209.

Raymond James Financial Services Advisors first reported a position in CPRX in Q1 2016 and has held it in 34 quarters since. The position peaked at $7.93M in Q1 2023. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Raymond James Financial Services Advisors held 256,688 shares of Catalyst Pharmaceutical worth $5.1M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 2 Catalyst Pharmaceutical shares in Q3 2024, an estimated $37.
  • Catalyst Pharmaceutical made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1209 holding.
  • Raymond James Financial Services Advisors first reported a position in Catalyst Pharmaceutical in Q1 2016 and has held it in 34 quarters since.
  • Raymond James Financial Services Advisors's Catalyst Pharmaceutical position peaked at $7.93M in Q1 2023.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.